Abstract
The symposium addressed the efficacy and safety of compounds currently available for treatment of hepatitis C virus (HCV) and chronic kidney disease (CKD) in North American and European countries, comparing data from trials and clinical practice. Prof Wedemeyer opened the meeting with a discussion of real-world experiences, with a focus on HCV genotypes (GTs) and resistance-associated variants (RAV). Prof Brown concentrated on trial and real-world data from patients with advanced liver disease, while Prof Craxí’s presentation focussed on chronic kidney conditions and infection. Prof Jacobson led the question and answer session and summarised the discussions.
Reference58 articles.
1. Miani C et al. Health and Healthcare: Assessing the Real-World Data Policy Landscape in Europe. Available at: http://www.rand.org/content/dam/rand/pubs/research_reports/RR500/RR544/RAND_RR544.pdf. Last accessed: 27 April 2016.
2. Annemans L et al. Real-Life Data: A Growing Need. Available at: https://www.ispor.org/News/articles/Oct07/RLD.asp. Last accessed: 27 April 2016.
3. Gower E et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-57.
4. AbbVie Ltd. Summary of product characteristics: VIEKIRAX (ombitasvir/paritaprevir/ritonavir) 12.5 mg/75 mg/50 mg film-coated tablets. Electronic Medicines Compendium. 2015. Available at: https://www.medicines.org.uk/emc/medicine/29784. Last accessed: 20 May 2016.
5. AbbVie Ltd. Summary of product characteristics: EXVIERA (dasabuvir) 250 mg film-coated tablets. Electronic Medicines Compendium. 2015. Available at: https://www.medicines.org.uk/emc/medicine/29785. Last accessed: 20 May 2016.